Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Open Access
- 22 June 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (15) , 4230-4244
Abstract
Purpose: Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to facilitate clinical implementation. Here, using locoregionally confined head and neck squamous cell carcinoma (HNSCC) as an example, we demonstrate tumor-naïve detection of ctDNA by simultaneous profiling of mutations and methylation.Experimental Design: We conducted CAncer Personalized Profiling by deep Sequencing (CAPP-seq) and cell-free Methylated DNA ImmunoPrecipitation and high-throughput sequencing (cfMeDIP-seq) for detection of ctDNA-derived somatic mutations and aberrant methylation, respectively. We analyzed 77 plasma samples from 30 patients with stage I–IVA human papillomavirus–negative HNSCC as well as plasma samples from 20 risk-matched healthy controls. In addition, we analyzed leukocytes from patients and controls.Results: CAPP-seq identified mutations in 20 of 30 patients at frequencies similar to that of The Tumor Genome Atlas (TCGA). Differential methylation analysis of cfMeDIP-seq profiles identified 941 ctDNA-derived hypermethylated regions enriched for CpG islands and HNSCC-specific methylation patterns. Both methods demonstrated an association between ctDNA abundance and shorter fragment lengths. In addition, mutation- and methylation-based ctDNA abundance was highly correlated (r > 0.85). Patients with detectable pretreatment ctDNA by both methods demonstrated significantly worse overall survival (HR = 7.5; P = 0.025) independent of clinical stage, with lack of ctDNA clearance post-treatment strongly correlating with recurrence. We further leveraged cfMeDIP-seq profiles to validate a prognostic signature identified from TCGA samples.Conclusions: Tumor-naïve detection of ctDNA by multimodal profiling may facilitate biomarker discovery and clinical use in low ctDNA abundance applications.Keywords
All Related Versions
Funding Information
- Canadian Institutes of Health Research (148430)
- CIHR (201512MSH-360794-228629)
- OICR (950-23134)
This publication has 41 references indexed in Scilit:
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experimentsBioinformatics, 2013
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013
- Software for Computing and Annotating Genomic RangesPLOS Computational Biology, 2013
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- Point-of-care outcome assessment in the cancer clinic: Audit of data qualityRadiotherapy and Oncology, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009